Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature - Wikidata - awgldk - TriplyDB

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

http://www.wikidata.org/entity/Q38110731

about

Targeting MAPK Signaling in Age-Related Macular Degeneration Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Glaucoma: the retina and beyond Nanomedicine in the application of uveal melanoma Fit for the Eye: Aptamers in Ocular Disorders Microfluidic co-cultures of retinal pigment epithelial cells and vascular endothelial cells to investigate choroidal angiogenesis.A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits Targeted Delivery of FLT-Morpholino Using Cyclic RGD Peptide Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase.A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation.Estrogen therapy to treat retinopathy in newborn mice Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal Neovascularization BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration.ANGPTL4-αvβ3 interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2.Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Posterior sub-tenon's bevacizumab injection in diabetic macular edema; a pilot study.A cute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report.The effect of normal aging and age-related macular degeneration on perceptual learning.Thrombospondin-1-Based Antiangiogenic Therapy.Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.Rehabilitation Approaches in Macular Degeneration Patients.Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.Natural product inhibitors of ocular angiogenesis.Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Aptamers as targeted therapeutics: current potential and challenges.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.All-trans retinoic acid upregulates the expression of ciliary neurotrophic factor in retinal pigment epithelial cells.Ocular Toxicity of Tyrosine Kinase Inhibitors.

P2860

Q26744185-16C21EFA-53BF-414F-A0B5-359B7E17268D Q26778521-6E34E4CB-FD33-49EC-A4EE-52F42458C23F Q26852289-6EF17F01-F6A1-487A-9F60-4E8BE9562BF1 Q28077518-C932DDD0-BC39-4EAA-B000-B9D20C17AB8F Q28079572-2B89A188-4533-406A-B69F-E0DBDB9400F0 Q28828283-034E7D6B-09FC-4D32-A9F6-405B64F2439A Q30855748-8AA3DB5E-5FAE-4ECC-8BCF-2279E0AD4C96 Q33674476-1E4BE7B7-DFD2-45E6-8DB1-6A50036C44BD Q33727486-A6146178-C1A5-4299-9C9C-0A9A056387B6 Q33742338-03A7E913-BB65-45CB-A3C9-4904EB4827B5 Q34553334-8B904B80-809B-4819-9FF0-701CAE28B9C1 Q35111445-EE7B6935-CA1C-4D1A-B145-D1C41D48D110 Q35120919-89984940-4C78-4021-B807-848857C3A87B Q35436686-442556DD-E157-4027-AF2A-E8D48414C73C Q35870307-0B3456E7-4018-4C1E-ADD4-2332C6586588 Q36053934-87088609-2B11-4740-A9D9-711F1399C765 Q36102528-7860196D-5ED0-41AE-9AF6-44ADAA5EC2C2 Q36117879-185BC1EB-8566-4708-9FE9-41777B56097E Q36186327-0ADCF25C-BC53-4FCD-B91B-82722555857B Q36200924-B22950D2-F604-4B36-BB2F-7053981DD77F Q36221554-4A061A01-3310-4454-A9E5-DB0F4E600613 Q36306682-F448B3CB-D49C-4017-848D-95832F6F5ECD Q36345513-A0D3D406-B8E4-4C43-A6C0-DB7778E051F3 Q36417463-D93358BD-7B43-4D40-8284-4E3616D92650 Q36494723-A442C570-914E-4EC2-A40D-BBBF70886F55 Q36872704-E857CF76-EF35-48F3-8B22-1F4C3E915693 Q36881990-E8BA5286-00F9-4EAF-9B31-43997FADB613 Q36890872-CDDAA596-F721-4547-9FE1-A2B206DC5A62 Q37383794-7096E816-380F-451D-AFF0-EE5DE1F0CC8C Q37477129-DB8FF39A-9CB4-4EF1-A5A4-068830C56C6D Q37533137-ABE5CC21-6BFA-444D-98C9-0E52F48E79A8 Q38256840-791A23A4-BD08-485E-94E6-E3E8BC79501E Q38258984-55489DB5-7049-46F1-8F5F-7F99FA74C672 Q38261103-AF0FD429-4B4C-4B9A-81E7-B6BC2E2C8620 Q38261105-AD617ADF-5249-4964-BCCF-7157AC9B2C81 Q38290290-557E7421-DC91-45BA-97F8-A50529286F0C Q38528148-E965068A-9A4D-43B4-BA11-4F35A937D8AC Q38633532-5B0D4082-F662-4C8A-9F44-9AD875A20FE8 Q38700982-459051CA-95CA-41F9-9743-BF739059CBB7 Q38746683-F0E197E7-1BF8-4AC8-AE2C-FF47ACC5AD19

P2860

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

http://www.wikidata.org/entity/Q38110731

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Adverse events and complicatio ...... agents: a review of literature

@en

type

label

Adverse events and complicatio ...... agents: a review of literature

@en

prefLabel

Adverse events and complicatio ...... agents: a review of literature

@en

P1433

Q38110731-FC264E1B-0C57-483B-A80E-F5187A21FAE6

P1476

Q38110731-C3D5DF04-392B-4514-B781-75FC816D694A

P2093

Q38110731-994D0AF6-E2F0-4827-A1A7-786A9AC21607

Q38110731-D41AE961-6067-40A6-98BB-9F359ECD09D3

P2860

Q38110731-0468D16C-D647-4199-9153-7973B6372487

Q38110731-086FB64F-804D-48F5-838B-F5EE6CF0221C

Q38110731-0BBBD313-A6B1-449D-BDF0-0D37E498CD0A

Q38110731-11466D80-CE25-4CDA-BB85-7C622A95149A

Q38110731-150FE32E-AC1F-4AB4-8B2A-F18C19BE7EE4

Q38110731-1B658277-29D1-4177-AED0-173ECE345C68

Q38110731-2020AEDC-E170-4364-A4E8-DD7379657891

Q38110731-20723E20-37C2-482C-AF1A-8533B1430984

Q38110731-20DDEF86-0C3E-4949-9111-E632A46447CD

Q38110731-2BEF0085-2D9B-4378-9E72-6D6A162BADF7

P2888

Q38110731-4B4AEF53-0745-434E-954F-732C83D92431

P304

Q38110731-CF28BDAE-065F-4A0A-A1B3-52A6FE821421

P31

Q38110731-3AD02B9E-239A-4742-8D90-5158E2FC7B7D

P356

Q38110731-9A8E89B1-6323-4DA5-A1AD-2A3B5E12F87F

P433

Q38110731-6254D87B-FC2B-4E09-BB3B-5FE6ACDCC502

P478

Q38110731-4B68B44E-5549-47DA-BCB4-76266059DC1E

P577

Q38110731-F39CA46A-2A48-4245-9B08-7E915C686998

P5875

Q38110731-526107C3-705E-4C03-B19B-288945F80140

P6179

Q38110731-0D73AAD9-E921-48C0-89A1-6CB6CE0EA5AF

P698

Q38110731-6D61C71A-49E0-48CB-AC86-70D2461524E2

P932

Q38110731-5833FA55-BA3E-46AB-9A5E-8DF1E556D782

P356

P1433

P1476

Adverse events and complicatio ...... agents: a review of literature

@en

P2093

K Ghasemi Falavarjani

http://www.w3.org/2001/XMLSchema#string

Q D Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.

RPE tears after pegaptanib treatment in age-related macular degeneration.

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.

Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.

Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections.

Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.

Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.

P2888

P304

787-794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2013.107

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236977294

http://www.w3.org/2001/XMLSchema#string

P6179

1035675129

http://www.w3.org/2001/XMLSchema#string

P698

23722722

http://www.w3.org/2001/XMLSchema#string

P932

3709385

http://www.w3.org/2001/XMLSchema#string